Study of Modified Urine Fetuin A to Predict Kidney Function Decline in Adults with Resistant and Non-resistant Hypertension

What this Trial Is About

Researchers are studying arterial hypertension, a common cause of chronic kidney disease, to find better ways to predict early kidney function decline. This study focuses on a new urine biomarker called modified human urine Fetuin A, which may identify kidney disease progression earlier than commonly used tests like creatinine and albumincreatinine ratio. The study particularly looks at patients with hypertension, including resistant and secondary types, to evaluate this markers usefulness. This is an observational study without any intervention, involving patients with arterial hypertension who are treated with at least one antihypertensive medication. The study observes these patients over time, collecting urine samples to measure modified Fetuin A and other biomarkers. Participants include patients with resistant and non-resistant hypertension. There is no experimental treatment or placebo. Participants will provide urine samples and undergo tests to monitor kidney function, including the glomerular filtration rate, over one year. Researchers will also analyze correlation and changes in urine biomarkers. The study tracks kidney function decline and assesses the potential of urine Fetuin A to predict kidney damage earlier. The total duration of participation is about one year with regular evaluations to monitor outcomes and health status.

Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients